United States
Print page content Print
Increase text size Decrease text size
Text Size

DEXDOMITOR®

(dexmedetomidine)

Provides sedation and analgesia, and works as a preanesthetic, for dogs and cats

DEXDOMITOR is indicated for use as a sedative and analgesic in dogs and cats to facilitate clinical examinations, clinical procedures, minor surgical procedures and minor dental procedures.

DEXDOMITOR also is effective as a preanesthetic in dogs and cats prior to general anesthesia.

DEXDOMITOR is approved for use in dogs as young as 16 weeks of age and cats as young as 12 weeks of age.

 

Expand All
    • Protocol flexibility for both surgical and non-surgical procedures.
      • Flexible dosing options for sedation and preanesthesia for both dogs and cats.
      • Reversible with ANTISEDAN® (atipamezole) in dogs.
    • Sedation and analgesia at predictable depths and duration while minimizing unwanted side effects.
      • Specific and selective alpha2-adrenoceptor agonist1,2 approved for companion animals.
      • Selectivity provides greater predictability and control.3
    • Dexdomitor is the purified version of medetomidine3,4
      • Contains only dexmedetomidine, the active portion of the molecule.
      • The inactive portion, levomedetomidine, has been removed.
      • The purified formulation lowers metabolic burden.4
    • Markedly reduces anesthetic requirement (30% - 60%):5,6
      • Preanesthesia with DEXDOMITOR has a dose-sparing effect by markedly reducing the amount of induction agent and gas anesthetic for maintenance.
      • As a premedicant, DEXDOMITOR contributes to balanced anesthesia which can lower patient risk and increase comfort and safety for the anesthetic event. 
  • Flexible Dosing Options

    Sedation and analgesia
    Dog: 375 mcg/m2 IV or 500 mcg/m2 intramuscular (IM)       
    Cat: 40 mcg/kg IM


    Preanesthesia
    Dog: 125 mcg/m2 IM or 375 mcg/m2 IM
    Cat: 40 mcg/kg IM


    Please refer to the full prescribing information for more dosage and administration information.
     

  • 1. Gertler R, et al. Dexmedetomidine: a novel sedative-analgesic agent. BUMC Proceedings. 2001; 14:13-21.
    2. Virtanen, R et al. Characterization of the selectivity, specificity and potency of medetomidine as an alpha-2 adrenoceptor agonist. EU J of Pharmacol. 1988; 150:9-14.
    3. Murell JC, Hellebrekers LJ. Medetomidine and dexmedetomidine: a review of cardiovascular effects and antinociceptive properties in the dog. Vet Anaesth Analg. 2005;32:117-127.
    4. Ko JC et al. FAQs Sedation analgesia and anesthesia. Making the switch from medetomidine to dexmedetomidine. CCE for Vets, Suppl 2009;31,1A 1-16.
    5. Dexdomitor Freedom of Information Summary. NADA 141-267. December 2006.
    6. Dexdomitor Freedom of Information Summary. NADA 141-267. Supplemental, May 2010.


IMPORTANT SAFETY INFORMATION
Do not use DEXDOMITOR or DEXDOMITOR 0.1 in dogs or cats, and ANTISEDAN in dogs, with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue. DEXDOMITOR and DEXDOMITOR 0.1 should not be administered in the presence of preexisting hypotension, hypoxia, or bradycardia. As with all α2-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists with DEXDOMITOR and DEXDOMITOR 0.1. The use of DEXDOMITOR and DEXDOMITOR 0.1 as a preanesthetic in dogs and cats significantly reduces the amount of induction and maintenance anesthetic requirements. Careful patient monitoring is necessary to avoid anesthetic overdose. Arrhythmias, bradycardia, apnea, emesis, convulsions, hypersalivation may occur with DEXDOMITOR and DEXDOMITOR 0.1 use. Severe dyspnea and respiratory crackles due to acute or delayed pulmonary edema could develop in cats. DEXDOMITOR and DEXDOMITOR 0.1 have not been evaluated for use in breeding, pregnant, or lactating dogs or cats; in dogs younger than 16 weeks of age or in cats younger than 12 weeks of age; or in geriatric dogs or cats. Occasional vomiting may occur with ANTISEDAN use. Rarely, a brief state of excitement or apprehensiveness may be seen in ANTISEDAN-treated dogs. Other potential side effects of α2-antagonists, such as ANTISEDAN, include hypersalivation, diarrhea, and tremors.

For more safety information on DEXDOMITOR, please refer to the full prescribing information.

For more safety information on ANTISEDAN, please refer to the full prescribing information.